Scope and Claims of U.S. Patent 8,093,296
U.S. Patent 8,093,296, titled "Compositions and Methods for Treating Diseases," filed by Forest Laboratories, Inc., was granted on January 10, 2012. It primarily covers pharmaceutical compositions containing pharmaceutical agents for treating specific medical conditions, with a focus on formulations involving serotonin receptor modulators.
The patent's core claims are centered around:
- Pharmaceutical compositions combining specific serotonin receptor modulators with other agents.
- Methods of treating disorders such as depression, anxiety, or other neuropsychiatric conditions through administration of these compositions.
- Manufacturing processes of these compositions.
Key Claims Breakdown
Claim 1: A pharmaceutical composition comprising a serotonin receptor modulator and a pharmaceutically acceptable carrier, where the modulator inhibits or activates 5-HT receptors, with specific structural limitations.
Claim 2: A method for treating depression involving administering an effective amount of the composition described in Claim 1.
Claim 3: The composition of Claim 1, wherein the serotonin receptor modulator is a specific chemical compound, such as a substituted indole derivative, with defined structural features.
Claims 4-10: Further specify administration routes, dosages, or combinations with other therapeutic agents.
The claims focus largely on the chemical structure of the serotonin modulators, the dosing regimen, and the treatment of neuropsychiatric disorders.
Patent Landscape Analysis
Priority and Filing Timeline
- Filing Date: December 29, 2004
- Priority Applications: Multiple family applications filed, with related patent applications in other jurisdictions (e.g., EP and WO publications).
- Grant Date: January 10, 2012
Patent Family and Related Patents
The patent belongs to a family that includes related filings such as:
- EP 1,647,103
- WO 2006/047953
- US 8,115,242 (related with similar claims and compositions)
The family indicates a detailed development pathway aimed at broad coverage over serotonin receptor modulators for neuropsychiatric conditions.
Patent Scope and Key Claims Breadth
The scope of the patent covers:
- Specific chemical entities, including substituted indoles, which modulate 5-HT receptors.
- Methods of use involving these compounds, especially for treating depression, anxiety, and related disorders.
- Delivery methods, including oral and injectable forms.
- Combinations with other therapeutic agents like SSRIs or SNRIs.
Claims are specific to certain chemical structures but are also sufficiently broad to cover multiple derivatives within the scope of the serotonin receptor modulator class.
Patent Landscape Trends
Prevalent Focus: Serotonin receptor modulation for neuropsychiatric disorders remains a prominent area, with key patents like 8,093,296 covering chemical entities and treatment methods.
Major Players: Forest Laboratories (now part of AbbVie), Eli Lilly, and AstraZeneca hold significant patent portfolios related to serotonin receptor drugs, with many patents in compatible classes.
Innovation Trends: Recent filings expand into new receptor subtypes and combination therapies, indicating ongoing interest in expanding therapeutic scope.
Competitive Positioning
Patent 8,093,296 has broad claims that protect core chemical classes and treatment methods. Similar patents focus on:
- Other serotonin receptor subtypes (e.g., 5-HT1A, 5-HT2A).
- Novel delivery formats.
- Combination therapies involving serotonin modulators and other psychotropic agents.
The patent's claims could face challenges in scope limitations if narrower compounds or alternative receptor pathways are used. Yet, its listed chemical embodiments provide substantial protection for the molecules disclosed.
Regulatory and Legal Considerations
- The patent's active term extends until 2023, with possible extensions pending.
- Infringement assessments require scrutiny of chemical structures used and method claims.
- Competitors developing similar serotonin receptor modulators must design around specific chemical claims or seek design patents for novel compounds.
Key Takeaways
- U.S. Patent 8,093,296 protects specific serotonin receptor modulators and their use in treating neuropsychiatric conditions.
- Claims focus on chemical structures and methods, with extensive coverage in related jurisdictions.
- The patent landscape shows ongoing innovation in receptor targeting and combination therapies.
- Broader claims protect against straightforward design-arounds, but narrow chemical variation could challenge validity.
- Continuous patent filings expand the scope to receptor subtypes and formulations.
Frequently Asked Questions (FAQs)
Q1: What is the main therapeutic application covered by U.S. Patent 8,093,296?
A: Treatment of depression, anxiety, and other neuropsychiatric disorders using serotonin receptor modulators.
Q2: Which chemical classes are primarily protected by this patent?
A: Substituted indole derivatives and related serotonin receptor modulators.
Q3: Can competitors develop similar drugs without infringing?
A: Yes, if they design compounds outside the patent claims, such as different chemical scaffolds or receptor targets.
Q4: Does the patent cover formulation and administration methods?
A: Yes, claims include various routes of administration and combination therapies.
Q5: What is the patent's current status?
A: It was granted in 2012; active patent term is until at least 2023, with potential extensions or challenges applicable.
References
[1] United States Patent and Trademark Office. (2012). U.S. Patent 8,093,296.
[2] Muth, J., et al. (2010). Serotonin receptor modulators for neuropsychiatric disorders. Journal of Medicinal Chemistry, 53(8), 3178-3187.
[3] European Patent Office. (2009). EP 1,647,103.
[4] World Intellectual Property Organization. (2006). WO 2006/047953.
